Why the study?
Does the co-administration of CYP3A4-metabolized statins and clopidogrel cause a clinically relevant drug interaction?
Does the co-administration of CYP3A4-metabolized statins and clopidogrel cause a clinically relevant drug interaction?
Answers are grounded in this paper and cite their sources.
There is no compelling clinical evidence to avoid co-administering clopidogrel with CYP3A4-metabolized statins despite preclinical concerns.
Since their introduction several years ago, the 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitors-the statins-have been widely used for hyperlipidemia and for the primary/secondary prevention of cardiovascular diseases. They have been shown to be safe as well as efficacious in a number of different clinical trials; however, studies have suggested that they can interact with other co-administered therapies. More recently, the thienopyridines have been successfully integrated with the conventional medical treatment of coronary disease as they showed effectiveness in reducing platelet activity both in stable and unstable settings. They also improve the outcome of patients treated with percutaneous coronary intervention. The potential interaction of statins and thienopyridines is a matter of concern. Despite some preclinical data suggesting an interaction between statins metabolized by the liver cytochrome P3A4-such as atorvastatin, lovastatin and simvastatin-and clopidogrel, there is no compelling clinical evidence to stop their co-administration.
No takes yet. Share an insight, caveat, or question.
Bhindi et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: